ArticleDisease models & mechanisms2026
The ALX1 transcription factor acts in the early cranial mesoderm to specify extraocular muscle formation.
Article in Disease models & mechanisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The alx gene family confers segmental identity to frontonasal cranial neural crest cells.Nature communications · 2026Article
- A Twist1-regulated distal enhancer crucial for Alx1 gene expression and function during craniofacial development.Developmental biology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Loss of ALX1 gene function causes severe facial clefting and extreme microphthalmia. Previous studies suggest that ALX1 protein function is crucial for patterning the cranial neural crest cell (CNCC)-derived frontonasal mesenchyme, but how ALX1 regulates eye development is not well understood. Here, we show that Alx1 is transiently expressed in the embryonic cranial mesoderm and that Alx1-/- mice exhibit agenesis of extraocular muscles (EOMs) without affecting other muscles. We show that cranial mesoderm-specific Alx1 inactivation resulted in complete EOM agenesis accompanied by failure of activation of the core myogenic regulatory network specifically in, and increased apoptosis of, the EOM progenitor cells. Analysis of mice with temporally induced Alx1 inactivation demonstrated that EOM myogenesis requires Alx1 function before, but not after, formation of the EOM primordium. These data identify ALX1 as a unique and specific upstream regulator of EOM myogenesis, and provide new insights into pathogenic mechanisms underlying ALX1-type frontonasal dysplasia, as well as molecular mechanisms controlling cell fate specification in the early cranial mesoderm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.